Bartter Syndrome Treatment Market By Drug Type (NSAIDs (Nonsteroidal Anti-inflammatory Drugs),RAAS Inhibitors), & By DIstribution Channel (Hospital,Pharmacies,Retail Pharmacies,Drug Stores) - Global Market Insights 2018 to 2028

Bartter Syndrome Treatment Market: Introduction

Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Over the past few years, it is observed that different terminologies have been used to describe Bartter syndrome. Some classify Bartter syndrome on the basis of its clinical appearance, whereas others classify it on the basis of its underlying mutated gene. On the basis of the underlying gene mutation, Bartter syndrome can be classified as Bartter syndrome type 1, type 2, type 3, type 4a and 4b and Gitelman syndrome.

Presently, according to the National Organization for Rare Disorders (NORD), Bartter syndrome is classified under a new classification system, which is based upon the specific part of the kidney affected. This includes loop disorders, DCT disorders and combined DCT and loop disorders. Loop disorders include Bartter syndrome type 1 and type 2 and DCT disorders include Gitelman syndrome. Combined DCT and loop disorders include Bartter syndrome type 3, type 4a and 4b.

The defects caused by Bartter syndrome impair the kidney’s ability to reabsorb salt and imbalance the fluid concentrations of various electrolytes in the body. The electrolytes affected by Bartter syndrome are generally mineral salts such as calcium, potassium, sodium, chloride and magnesium. Bartter syndrome is caused by alteration in one of the several different genes. Most of the subtypes of Bartter syndrome are inherited in an autosomal recessive manner. Bartter syndrome symptoms vary from person-to-person and its severity ranges from mild to severe. Bartter syndrome treatment aims at correcting electrolyte imbalance and includes the use of supplements and medications such as diuretics and non-steroidal anti-inflammatory drugs (NSAIDs).

The diagnosis of Bartter syndrome includes laboratory tests such as blood tests for determining serum electrolyte levels, especially renin and magnesium and aldosterone levels, and urine tests for determining the presence of prostaglandin E2 and urine electrolytes. In addition, molecular genetic testing is also used for the diagnosis of Bartter syndrome. Molecular genetic testing detects the mutations in specific genes, which causes Bartter syndrome. However, molecular genetic testing is only available at specialized laboratories as a diagnostic service.

Bartter syndrome treatment requires lifelong administration of certain supplements and medications. Presently, there is no cure for Bartter syndrome; however, restoring the proper balance of fluids and electrolytes in the body with certain medication can effectively work as Bartter syndrome treatment. For instance, indomethacin is a nonsteroidal anti-inflammatory drug which reduces the prostaglandin levels in the body. This further reduces excess urine production and the need for potassium supplements. Indomethacin is usually an effective and well-tolerated Bartter syndrome treatment. Some patients may require medications such as potassium-sparing diuretics such as spironolactone or amiloride. Growth hormone therapy is also considered as a successful Bartter syndrome treatment.

Bartter Syndrome Treatment Market: Drivers and Restraints

The growing prevalence of kidney disorders and increasingly unhealthy lifestyle are the major factors driving the growth of the global Bartter syndrome treatment market. Moreover, the rising number of clinical trials is expected to drive the Bartter syndrome treatment market.

Strong R&D and increasing awareness in low-middle income countries are further responsible for driving the growth of the global Bartter syndrome treatment market over the forecast period. Generally, Bartter syndrome affects both males and females in equal numbers. According to NORD, Bartter syndrome affects around one in 1,000,000 individuals in the overall population.

Difficulties in diagnostic tests and stringent regulations are expected to hamper the growth of the global Bartter syndrome treatment market.

Bartter Syndrome Treatment Market: Overview

The global market for Bartter syndrome treatment is expected to witness a moderate growth rate over the forecast period. Generally, drugs that block the renin-aldosterone angiotensin system are used for Bartter syndrome treatment. Bartter syndrome treatment prevents the secretion of aldosterone from the adrenal glands and, thereby reduces potassium loss.

The use of Bartter syndrome treatment drugs needs to be monitored as they may lower blood pressure and potentially impact kidney and cardiovascular functions. Among the various distribution channels, hospital pharmacies are expected to contribute the maximum market share in the global Bartter syndrome treatment market.

Bartter Syndrome Treatment Market: Regional Outlook

Geographically, the global Bartter syndrome treatment market has been segmented into North America, Latin America, Europe, CIS & Russia, Asia Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America is anticipated to be the dominant market in the global Bartter syndrome treatment market, owing to the increasing prevalence of kidney disorders.

Europe is expected to be the second-largest market in the global Bartter syndrome treatment market throughout the forecast period, owing to high awareness regarding health-related problems in the region. The Bartter syndrome treatment market in the Asia Pacific region is expected to grow with the maximum CAGR, mostly due to the growing geriatric population and increasing number of healthcare facilities in the region.

Bartter Syndrome Treatment Market: Market Participants

Examples of some of the key players operating in the global Bartter syndrome treatment market include

• Abbott Laboratories
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Others.

Key players operating in the global Bartter syndrome treatment market are majorly focusing on product launches through strategies such as mergers and acquisitions. Also, forming a strong pipeline can provide opportunities for companies to sustain their position in the global Bartter syndrome treatment market.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved
• Technology
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Argentina, Peru, Chile, Rest of LATAM)
• Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX, Eastern Europe, Rest of Europe)
• CIS & Russia
• Japan
• Asia Pacific Excluding Japan (Greater China, India, South Korea, ASEAN Countries, Rest of APEJ)
• Middle East and Africa (GCC Countries, Turkey, Iran, Israel, S. Africa, Rest of MEA)

Report Highlights: 

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Bartter Syndrome Treatment Market: Segmentation

Tentatively, the global Bartter syndrome treatment market can be segmented on the basis of Bartter syndrome treatment drug type, distribution channel and geography.

Based on Bartter syndrome treatment drug type, the global Bartter syndrome treatment market has been segmented as:

• NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
• RAAS Inhibitors
  • Aldosterone Antagonists
  • Angiotensin II Receptor Blockers
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
• Others

Based on distribution channel, the global Bartter syndrome treatment market has been segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
• Others